{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:50:44Z","timestamp":1790203844776,"version":"4.1.0"},"reference-count":50,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite improvement in treatments, the peritoneum remains the primary site of relapse in most ovarian cancer cases. Patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from epithelial ovarian cancer were reviewed. Kaplan\u2013Meier curves and multivariate Cox analyses were used to identify survival rates and prognostic factors. This study included 158 patients. The procedure was mostly performed for recurrent disease (46.8%) and high-grade serous carcinoma (58.2%). The median peritoneal cancer index was 14, and complete cytoreduction was obtained in 87.9% of cases. Grade IV morbidity occurred in 15.2% of patients, mostly requiring surgical reoperation, and one patient (0.6%) died within 90 days. The median follow-up was 63.5 months. The Kaplan\u2013Meier 5-year overall survival (OS) and disease-free survival (DFS) rates were 42.1% and 24.3%, respectively. Multiple regression logistic analyses demonstrated that the completeness of cytoreduction (CC) score (p \u2264 0.0001), pancreatic resection (p \u2264 0.0001) and number of resections (p = 0.001) were significant factors influencing OS; whereas the CC score (p \u2264 0.0001) and diaphragmatic procedures (p = 0.01) were significant for DFS. The addition of hyperthermic intraperitoneal chemotherapy to standard multimodality therapy may improve outcomes in both primary and recurrent epithelial ovarian cancer without impairing early postoperative results, but the exact timing has not yet been established. Prospective randomized studies will clarify the role and indications of this approach.<\/jats:p>","DOI":"10.3390\/cancers13030523","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T09:25:22Z","timestamp":1611912322000},"page":"523","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience"],"prefix":"10.3390","volume":"13","author":[{"given":"Fabio","family":"Carboni","sequence":"first","affiliation":[{"name":"Peritoneal Tumours Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orietta","family":"Federici","sequence":"additional","affiliation":[{"name":"Peritoneal Tumours Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Sperduti","sequence":"additional","affiliation":[{"name":"Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Settimio","family":"Zazza","sequence":"additional","affiliation":[{"name":"Peritoneal Tumours Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Sergi","sequence":"additional","affiliation":[{"name":"Department of Oncology, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Corona","sequence":"additional","affiliation":[{"name":"Peritoneal Tumours Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Valle","sequence":"additional","affiliation":[{"name":"Peritoneal Tumours Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: A review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Bio. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","article-title":"Can advanced-stage ovarian cancer be cured?","volume":"13","author":"Narod","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/IGC.0000000000000007","article-title":"Ovarian cancer: Sites of recurrence","volume":"23","author":"Amate","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ygyno.2018.09.007","article-title":"It\u2019s time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer","volume":"151","author":"Zivanovic","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Revaux, A., Carbonnel, M., Kanso, F., Naoura, I., Asmar, J., Kadhel, P., and Ayoubi, J.-M. (2020). Hyperthermic intraperitoneal chemotherapy in ovarian cancer: An update. Horm. Mol. Biol. Clin. Investig., 41.","DOI":"10.1515\/hmbci-2019-0028"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhang, G., Zhu, Y., Liu, C., Chao, G., Cui, R., and Zhang, Z. (2019). The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreduc-tive surgery (CRS) in advanced ovarian cancer: The meta-analysis. J. Ovarian Res., 12.","DOI":"10.1186\/s13048-019-0509-1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejso.2018.10.528","article-title":"Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis","volume":"45","author":"Wang","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jewell, A., McMahon, M., and Khabele, D. (2018). Heated intraperitoneal chemotherapy in the management od advanced ovarian cancer. Cancers, 10.","DOI":"10.20944\/preprints201806.0088.v1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ejso.2013.10.015","article-title":"Postoperative infections after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carinomatosis: Proposal and results from ma prospective protocol study of prevention, surveil-lance and treatment","volume":"40","author":"Valle","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: Pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ygyno.2019.07.011","article-title":"A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignanc","volume":"154","author":"Bartels","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ejso.2019.11.520","article-title":"Survival outcome and perioperative complication related to neoadjuvant chemo-therapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis","volume":"46","author":"Machida","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/ajo.12529","article-title":"Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residu-al disease after primary debulking surgery","volume":"56","author":"Paik","year":"2016","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejogrb.2019.12.001","article-title":"Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: A French national multicenter study (FRANCOGYN)","volume":"245","author":"Lecointre","year":"2020","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"viii40","DOI":"10.1093\/annonc\/mdx451","article-title":"Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?","volume":"28","author":"Monk","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejso.2020.08.016","article-title":"Feasibility of diaphragmatic interventions in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: A 20-year experience","volume":"47","author":"Carboni","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00464-017-5923-0","article-title":"Laparoscopy as a useful selection tool for patients with prior surgery and perito-neal metastases suitable for multimodality treatment strategies","volume":"32","author":"Boerner","year":"2018","journal-title":"Surg. Endosc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/IGC.0000000000001173","article-title":"Specific regions, rather than the entire peritoneal carcinosis index, are predic-tive of complete resection and survival in advanced epithelial ovarian cancer","volume":"28","author":"Rosendahl","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kim, S.I., Cho, J., Lee, E.J., Park, S., Park, S.J., Seol, A., Lee, N., Yim, G.W., Lee, M., and Lim, W. (2019). Selection of patients with ovarian cancer who may show survival benefit from hyperthermic in-traperitoneal chemotherapy. A systematic review and meta-analysis. Medicine, 98.","DOI":"10.1097\/MD.0000000000018355"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/jso.25703","article-title":"Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC","volume":"120","author":"Biacchi","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1245\/s10434-016-5686-1","article-title":"Cytoreduction (peritonectomy procedures) combined with hyperthermic in-traperitoneal chemotherapy (hipec) in advanced ovarian cancer: Retrospective italian multicenter observational study of 511 cases","volume":"24","author":"Garofalo","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1002\/cncr.32505","article-title":"Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on","volume":"125","author":"Koole","year":"2019","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A randomized trial of lymphadenectomy in patients with advanced ovarian neo-plasms","volume":"380","author":"Harter","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/02656736.2018.1423708","article-title":"Residual tumour less than 0.25 centimetres and positive lymph nodes are risk factors for early relapse in recurrent ovarian peritoneal carcinomatosis treated with cytoreductive surgery, HIPEC and systemic chemotherapy","volume":"34","author":"Artiles","year":"2018","journal-title":"Int. J. Hyperth."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Jennifer, A., Iptissem, N., Aur\u00e9lie, R., Philippe, K., and Marc, A.J. (2019). The place of secondary complete cytoreductive surgery in advanced ovarian cancer. Horm. Mol. Biol. Clin. Investig., 41.","DOI":"10.1515\/hmbci-2019-0030"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00404-018-4915-1","article-title":"Secondary cytoreduction in ovarian cancer: Who really benefits?","volume":"98","author":"Giudice","year":"2018","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_31","first-page":"111","article-title":"Effect of increased number of neoadjuvant chemotherapy cycles on tumor resectability and pathologic response in advanced stage epithelial ovarian cancer","volume":"23","author":"Akilli","year":"2018","journal-title":"J. BUON"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S971","DOI":"10.1245\/s10434-015-4623-z","article-title":"Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer","volume":"22","author":"Valadares","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jso.24666","article-title":"Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer","volume":"116","author":"Magge","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2018.06.015","article-title":"Moving beyond \u201ccomplete surgical resection\u201d and \u201coptimal\u201d: Is low-volume residual disease another option for primary debulking surgery?","volume":"150","author":"Gockley","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ygyno.2019.02.019","article-title":"The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review","volume":"153","author":"Timmermans","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Tate, S., Nishikimi, K., Kato, K., Matsuoka, A., Kambe, M., Kiyokawa, T., and Shozu, M. (2020). Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and primary peritoneal cancer. J. Gynecol. Oncol., 31.","DOI":"10.3802\/jgo.2020.31.e34"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.ejso.2019.07.019","article-title":"Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential-a prospective multi-centric study","volume":"45","author":"Bhatt","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1002\/cncr.32500","article-title":"Treatment of recurrent epithelial ovarian cancer","volume":"125","author":"Pignata","year":"2019","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1200\/JCO.19.00594","article-title":"Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial","volume":"37","author":"Koole","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ygyno.2019.01.025","article-title":"Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy","volume":"153","author":"Lim","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2018.07.019","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer","volume":"151","author":"Behbakht","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejso.2019.05.006","article-title":"Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer","volume":"47","author":"Koole","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_43","first-page":"488","article-title":"Quality of life after cytoreductive surgery and HIPEC: A single centre prospective study","volume":"23","author":"Kopanakis","year":"2018","journal-title":"J. BUON"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.suronc.2018.05.006","article-title":"HIPEC in patients with primary advanced ovarian cancer: Is there a role? A systematic review of short- and long-term outcomes","volume":"27","author":"Kireeva","year":"2018","journal-title":"Surg. Oncol."},{"key":"ref_45","first-page":"1","article-title":"An 18-year experience in diagnostic laparoscopy of peritoneal carcinomatosis: Results from 744 patients","volume":"20","author":"Carboni","year":"2019","journal-title":"J. Gastrointest. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ygyno.2014.04.013","article-title":"2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer","volume":"133","author":"Mutch","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1055-3207(03)00048-6","article-title":"Peritonectomy procedures","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1515\/pp-2017-0003","article-title":"Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice","volume":"2","author":"Lemoine","year":"2017","journal-title":"Pleura Peritoneum"},{"key":"ref_49","unstructured":"National Cancer Intitutes of Health (2010, June 14). Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28 2009 (v4.03), n.d, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/sim.4780030207","article-title":"Regression modelling strategies for improved prognostic prediction","volume":"3","author":"Harrell","year":"1984","journal-title":"Stat. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/3\/523\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:17:16Z","timestamp":1760159836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/3\/523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["cancers13030523"],"URL":"https:\/\/doi.org\/10.3390\/cancers13030523","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]}}}